Edition:
United States

AstraZeneca PLC (AZN)

AZN on New York Consolidated

31.30USD
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
$31.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,034,060
52-wk High
$35.04
52-wk Low
$25.55

AZN

Chart for AZN

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $78,333.44
Shares Outstanding(Mil.): 2,530.77
Dividend: 0.95
Yield (%): 4.47

Financials

  AZN Industry Sector
P/E (TTM): 22.65 28.87 29.63
EPS (TTM): 1.38 -- --
ROI: 7.52 13.48 13.01
ROE: 20.99 14.39 14.16

GSK and Regeneron to mine gene data from 500,000 Britons

LONDON Britain's GlaxoSmithKline and U.S.-based Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank, the world's most detailed biomedical database, to hunt for new clues linking genes and disease.

Mar 22 2017

GSK and Regeneron to mine gene data from 500,000 Britons

LONDON, March 23 Britain's GlaxoSmithKline and U.S.-based Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank, the world's most detailed biomedical database, to hunt for new clues linking genes and disease.

Mar 22 2017

Circassia strikes deal with AstraZeneca for respiratory drugs

LONDON Britain's Circassia has secured the U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease (COPD), a progressive lung condition affecting millions of people, for up to $230 million.

Mar 17 2017

Circassia strikes deal with AstraZeneca for respiratory drugs

LONDON, March 17 Britain's Circassia has secured the U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease (COPD), a progressive lung condition affecting millions of people, for up to $230 million.

Mar 17 2017

UPDATE 1-AstraZeneca receives FDA setback for high potassium drug

LONDON, March 17 U.S. regulators have dealt a fresh blow to AstraZeneca's new medicine to treat high potassium levels, indicating it still has concerns over the manufacturing process of the drug.

Mar 17 2017

AstraZeneca receives fresh blow to potassium drug

LONDON AstraZeneca said on Friday that U.S. regulators had rejected the British company's new drug for high potassium levels, in the latest setback to the product.

Mar 17 2017

AstraZeneca receives fresh blow to potassium drug

LONDON, March 17 AstraZeneca said on Friday that U.S. regulators had rejected the British company's new drug for high potassium levels, in the latest setback to the product.

Mar 17 2017

BRIEF-Astrazeneca signs deal with Circassia over Almirall's products

* Astrazeneca enters into a strategic collaboration with Circassia for the development and commercialization of Tudorza and Duaklir in the United States

Mar 17 2017

BRIEF-AstraZeneca receives FDA response to hyperkalaemia drug application

* Receives complete response letter from US FDA for zs-9 (sodium zirconium cyclosilicate) for hyperkalaemia

Mar 17 2017

BRIEF-Circassia to secure certain U.S. commercial rights to Tudorza, Duaklir from AstraZeneca

* Proposed collaboration and securing of certain U.S. Commercial rights to Tudorza And Duaklir from Astrazeneca

Mar 17 2017

More From Around the Web

Competitors

Earnings vs. Estimates